北京福元医药股份有限公司 关于变更持续督导保荐代表人的公告

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has announced a change in the designated sponsor representative for its ongoing IPO supervision by CITIC Jianzhong Securities, ensuring continued oversight of the use of raised funds [1][2]. Group 1 - CITIC Jianzhong Securities is the ongoing supervisory institution for the company's 2022 IPO project, with the original designated representatives being Mr. Tao Li and Mr. Zhao Runzhang [1]. - Due to a work change, Mr. Tao Li will no longer serve as the sponsor representative, and Mr. Chu Hanhui has been appointed to take over his responsibilities [1]. - The change in representatives does not affect the ongoing supervisory work of CITIC Jianzhong Securities for the company [1]. Group 2 - The company expresses gratitude to Mr. Tao Li for his contributions during the supervision period [2]. - Mr. Chu Hanhui holds a master's degree and is currently the vice president of the Investment Banking Business Management Committee at CITIC Jianzhong Securities [3]. - Mr. Chu has participated in various projects, including the company's IPO, and has a good record of compliance with relevant regulations [3].